700,000 in fngu from 2023-2024

The information about Fulgent Genetics (FNGU) projecting a gross margin of 35.5% in 2023 and 42.5% in 2024, with a net loss of $15.3 million in Q1 2023 and a planned transformation year with high spending on developing its pharmaceutical segment projects, suggests that the company is focused on long-term growth and may not prioritize short-term profits. Therefore, attributing a specific revenue figure to FNGU for the period 2023-2024 is not possible based on the available data. However, we can analyze the overall performance and prospects of Fulgent Genetics for the period 2023-2024. 1. **Financial Growth**: Fulgent Genetics is expected to see an increase in gross margin from 35.5% in 2023 to 42.5% in 2024. This indicates a potential improvement in profitability as the company integrates Inform Diagnostics and expands its portfolio of next-generation sequencing (NGS) tests. 2. **Market Position**: The company's acquisition of Inform Diagnostics has strengthened its position in the pathological tests market and expanded its NGS test portfolio. This strategic move is likely to contribute to the company's growth in the coming years. 3. **Clinical Developments**: Fulgent Genetics is currently in the Phase 1 clinical trial for FID-007, a nano-encapsulated paclitaxel for cancer treatment. Positive results from this trial could lead to significant advancements in the company's pharmaceutical segment. 4. **Revenue and Profitability**: Although specific revenue figures are not provided, the company's focus on integrating new acquisitions and expanding its service portfolio suggests a promising revenue outlook. The reduction in net loss and the anticipation of profitability from the first half of 2025 indicate a positive trend in financial performance. In conclusion, while a specific revenue figure for FNGU from 2023-2024 is not provided, the company's strategic initiatives and financial improvements suggest a promising outlook for the period. Fulgent Genetics is likely to see growth driven by its expanding service portfolio, clinical developments, and operational efficiencies.